276 related articles for article (PubMed ID: 7834119)
1. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
3. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
[TBL] [Abstract][Full Text] [Related]
4. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.
Freedman RS; Platsoucas CD
Cancer Treat Res; 1996; 82():115-46. PubMed ID: 8849947
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
8. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of intraperitoneal recombinant interleukin-2 and ex vivo activated intracavitary lymphocytes in patients with malignant peritoneal spread: I. Clinical aspects.
Lurie H; Rakovsky E; Fenig E; Davidovitz J; Adler A
Mol Biother; 1989; 1(3):163-9. PubMed ID: 2604915
[TBL] [Abstract][Full Text] [Related]
11. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
[TBL] [Abstract][Full Text] [Related]
12. Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector.
Nash MA; Platsoucas CD; Wong BY; Wong PM; Cottler-Fox M; Otto E; Freedman RS
Hum Gene Ther; 1995 Nov; 6(11):1379-89. PubMed ID: 8573611
[TBL] [Abstract][Full Text] [Related]
13. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
Schiltz PM; Beutel LD; Nayak SK; Dillman RO
J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.
Figlin RA; Thompson JA; Bukowski RM; Vogelzang NJ; Novick AC; Lange P; Steinberg GD; Belldegrun AS
J Clin Oncol; 1999 Aug; 17(8):2521-9. PubMed ID: 10561318
[TBL] [Abstract][Full Text] [Related]
15. Novel immunologic strategies in ovarian carcinoma.
Freedman RS; Ioannides CG; Mathioudakis G; Platsoucas CD
Am J Obstet Gynecol; 1992 Nov; 167(5):1470-8. PubMed ID: 1332480
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.
Quattrocchi KB; Miller CH; Cush S; Bernard SA; Dull ST; Smith M; Gudeman S; Varia MA
J Neurooncol; 1999; 45(2):141-57. PubMed ID: 10778730
[TBL] [Abstract][Full Text] [Related]
17. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
18. The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity.
Marcus SG; Perry-Lalley D; Mulé JJ; Rosenberg SA; Yang JC
J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):105-12. PubMed ID: 8136942
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
[TBL] [Abstract][Full Text] [Related]
20. Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.
Freedman RS; Gibbons JA; Giedlin M; Kudelka AP; Kavanagh JJ; Edwards CL; Carrasco CH; Nash MA; Platsoucas CD
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):443-51. PubMed ID: 9041464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
